Evidence map›Paper›PMID 40265411›Full record

ArticleAntibodies (Basel, Switzerland)2025

T330M Substitution in the Sodium-Dependent Phosphate Transporter NaPi2b Abolishes the Efficacy of Monoclonal Antibodies Against MX35 Epitope.

Leisan F Bulatova, Vera S Skripova, Aisylu R Sagdeeva, Ramilia A Vlasenkova, Tatiana A Bugaenko, Rezeda R Galimova, Alfiya I Nesterova, Yuliya V Filina, Ramziya G Kiyamova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibodies (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Leisan F BulatovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Vera S SkripovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Aisylu R SagdeevaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Ramilia A VlasenkovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0003-0082-6833
Tatiana A BugaenkoInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Rezeda R GalimovaRepublican Clinical Oncology Dispensary, 420029 Kazan, Russia.
Alfiya I NesterovaRepublican Clinical Oncology Dispensary, 420029 Kazan, Russia.ORCID 0000-0003-4249-5518
Yuliya V FilinaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-1853-8365
Ramziya G KiyamovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.

Funding

Russian Science Foundation 23-75-01100
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

epitope recognitionmonoclonal antibodiesMX35 epitopeNaPi2bSLC34A2T330M mutationtargeted therapy

Identifiers

PMID40265411
PMCPMC12015770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.